E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
(ECOG-ACRIN Cancer Research Group) The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019).
doro Coscia Autoimmune phenomena are frequently observed in patients with chronic lymphocytic leukemia (CLL) and are mainly attributable to underlying dysfunctions of the immune system. Autoimmune cytopenias (AIC) affect 4–7% of patients with CLL and mainly consist of autoimmune hemolytic anemia and immune thrombocytopenia. Although less common, non-hematological autoimmune manifestations have also been reported. Treatment of CLL associated AIC should be primarily directed against the autoimmune phenomenon, and CLL specific therapy should be reserved to refractory cases or patients with additional signs of...
r U Abstract PURPOSE: In the phase 3 DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated significantly improved efficacy vs ofatumumab (median [m]PFS, 13.3 vs 9.9 months [HR, 0.52; P
CONCLUSIONS: AMG-176 is active in inducing CLL cell death while sparing normal blood cells. Combination with low dose venetoclax had at least additive effect. PMID: 31937611 [PubMed - as supplied by publisher]
Abstract For more than two decades naturally presented, human leukocyte antigen (HLA)-restricted peptides (immunopeptidome) have been eluted and sequenced using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Since, identified disease-associated HLA ligands have been characterized and evaluated as potential active substances. Treatments based on HLA-presented peptides have shown promising results in clinical application as personalized T cell-based immunotherapy. Peptide vaccination cocktails are produced as investigational medicinal products under GMP conditions. In order to support clinical trials bas...
CONCLUSIONS: We propose to include the number of pathways altered by driver mutations as a biomarker together with CLL-IPI in prospective studies of CLL from time of diagnosis for incorporation into clinical care and personalized follow-up and treatment. PMID: 31919133 [PubMed - as supplied by publisher]
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition.
Dr William Wierda of MD Anderson Cancer Center reviews key studies on chronic lymphocytic leukemia therapies presented at the 2019 American Society of Hematology (ASH) meeting in Orlando, Florida.Medscape
ConclusionsPTC risk was elevated after a range of first primary adult cancers but was not clearly related to treatment. Although surveillance may contribute to elevated short-term risks of PTC, longer-term elevations in regional/distant PTC may be attributable to shared risk factors.
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the United States Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of sever al other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL).1 Recently, ibrutinib plus venetoclax have been found to be effective as first-line treatment for high-risk and older patients with CLL.
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the U.S. Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of several other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL) (1). Recently, Ibrutinib plus venetoclax have been found to be effective as first line treatment for high risk and older patients with CLL (2).